An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C

References

• Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317: 146–9
   PubMed Web of Science ®Google Scholar
• Stevens DL, Tanner MH, Winship J, Swarts R, Rice KM, Schlievert PM, Kaplan EL. N Engl J Med 1989; 321: 1–7
   PubMed Web of Science ®Google Scholar
• Bartter T, Dascal A, Carrol K, Curley FJ. “Toxic strep syndrome”. A manifestation of group A streptococcal infection. Arch Intern Med 1988; 148: 1421–4
   PubMed Web of Science ®Google Scholar
• Demers B, Simor AE, Vellend H, Schlievert PM, Byrne S, Jamieson F, et al. Severe invasive group A streptococcal infections in Ontario, Canada 1987–1991. Clin Infect Dis 1993; 16: 792–800
   PubMed Web of Science ®Google Scholar
• The Working Group on Severe Streptococcal Infections. Defining the group A toxic shock syndrome: rationale and consensus definition. JAMA 1993;269:390–1.
   PubMed Web of Science ®Google Scholar
• Davies HD, McGeer A, Schwartz B, Green K, Cann D, Sim A, et al. Invasive group A streptococcal infections in Canada. N Engl J Med 1996; 335: 547–54
   PubMed Web of Science ®Google Scholar
• Cavaillon J-M, Mueller-Alouf H, Alouf JE. Cytokines in streptococcal infections. Adv Exp Med Biol 1997; 418: 929–31
   PubMedGoogle Scholar
• Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989; 57: 291–4
   PubMedGoogle Scholar
• Mueller-Alouf H, Alouf D, Gerlach D, Ozegowski JH, Fitting C, Cavaillon J-M. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci and lipopolysaccharide. Infect Immun 1994; 62: 4915–21
   PubMedGoogle Scholar
• Norrby-Tegland A, Thulin P, Bing S, Gran BS, Kolb M, McGeer A, et al. Evidence for superantigen involvement in severe group A streptococcal infection. J Infect Dis 2001; 184: 853–60
   PubMedGoogle Scholar
• Proft T, Louise Moffatt S, Berkahn CJ, Fraser JD. Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 1999; 189: 89–102
   PubMed Web of Science ®Google Scholar
• Esmon CT, Taylor FB, Jr, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991; 66: 160–5
   PubMed Web of Science ®Google Scholar
• Taylor FB, Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang ACK, Laszik Z, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680–6
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent J-L, Laterre P-F, La Rosa SP, Dhaipau JF, Lopez-Rodriguez A, et al. Efficacy and saftey of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709
   PubMed Web of Science ®Google Scholar
• Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199–203
   PubMed Web of Science ®Google Scholar
• Zeigler EJ, Fischer CJ, Jr, Sprung CL, et al. Treatment of Gram-negative bacteremia and septic shock with HA1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 29–36
   Google Scholar
• Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wundirink R, et al. Double-blind, randomized, controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998; 351: 929–33
   PubMed Web of Science ®Google Scholar
• Fisher CJ, Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697–1702
   PubMed Web of Science ®Google Scholar
• Opal SM, Fisher CJ, Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. The confirmatory interleukin-1 receptor antagonist trial in sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115–24
   PubMed Web of Science ®Google Scholar
• Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. High dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869–78
   PubMed Web of Science ®Google Scholar
• Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial. JAMA 2003; 290: 238–47
   PubMed Web of Science ®Google Scholar
• Kaul R, McGeer A, Norby-Teglund A, Korb M, Schwartz B, O'Rourke K, The Canadian Streptococcal Study Group, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999;28:800–7.
   PubMed Web of Science ®Google Scholar
• Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, , The Streptig Study Group, et al. Intravenous immunolobilin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333–40.
   PubMed Web of Science ®Google Scholar
• Kotb M, Norrby-Teglund A, McGeer A, El Sherbini H, Dorak MT, Kurshid K, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nature Med 2002; 8: 1398–1404
   PubMed Web of Science ®Google Scholar
• Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A sreptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346: 1200–6
   PubMed Web of Science ®Google Scholar